For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
This report studies the Hirudin market. Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. Hirudin is the most potent natural inhibitor of thrombin.
Hirudin (hirudin) is a Leech (Leech) and salivary glands have been extracted from a variety of active ingredients in the activity of the most significant and most studied ingredients, which is 65-66 amino acids from the small molecules of protein (peptide) . Hirudin have strong inhibitory effect on thrombin is the strongest so far found in the natural specific inhibitor of thrombin. Animal experiments and clinical studies have shown that hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.
Scope of the Report:
Hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.
According to the statistical data, Demand cannot be satisfied with supply. Currently, Hirudin market has a certain potential in USA, Europe and Asia Market. These areas demand are rapidly growth.
In recent years in China as the main ingredient to hirudin, there are many kinds of proprietary Chinese medicines, such as cerebral blood oral liquid, tablets thrombosis, blood capsule, with its annual output value of tens of millions. New drugs with leeches are constantly studied and introduced. Genetic engineering of recombinant leech-like peptide drugs to replace or hirudin as anticoagulant drug additives stasis, which can be achieved in the near future. As the injection for the treatment of cardiovascular diseases and cancer drugs, the need for further clinical research. Needless to say, recombinant hirudin-like peptide drug development will bring huge social and economic benefits.
The worldwide market for Hirudin is expected to grow at a CAGR of roughly 3.5% over the next five years, will reach 4240 million US$ in 2024, from 3450 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Hirudin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- The Medicines Company
- Keyken
- Minapharm
- Abbott
- SALUBRIS
- Pfizer, Inc
- Teva Pharmaceutical Industries Ltd
- DUOPUTAI
- Pentapharm
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Natural Hirudin
- Recombinant Hirudin
Market Segment by Applications, can be divided into
- Thrombosis Disease
- Tumor Disease
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hirudin product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hirudin, with price, sales, revenue and global market share of Hirudin in 2017 and 2018.
Chapter 3, the Hirudin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hirudin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Hirudin market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Hirudin sales channel, distributors, customers, research findings and conclusion, appendix and data source.